Advertisement

Drugs & Therapy Perspectives

, Volume 18, Issue 9, pp 1–4 | Cite as

Daclizumab has a definite role in preventing acute rejection in renal transplants and may be beneficial in other solid organ transplants

New Drugs and Profile Reports
  • 12 Downloads

Keywords

Acute Rejection Renal Transplant Recipient Graft Versus Host Disease Immunosuppressive Regimen Liver Transplant Recipient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Carswell, CI, Plosker, GL, Wagstaff, AJ. Daclizumab: a review of its use in the management of organ transplantation. BioDrugs 2001; 15 (11): 745–73PubMedCrossRefGoogle Scholar
  2. 2.
    Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67: 110–5PubMedCrossRefGoogle Scholar
  3. 3.
    Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161–5PubMedCrossRefGoogle Scholar
  4. 4.
    Ekberg H, Bäckman L, Tufveson G, et al. Daclizumab prevents acute rejection and improved patient survival post transplantation: 1 year pooled analysis. Transpl Int 2000; 13 (2): 151–9PubMedCrossRefGoogle Scholar
  5. 5.
    Meier-Kriesche H-U, Kaza H, Palekar SS, et al. The effect of daclizumub in a high-risk renal transplant population. Clin Transpl 2000; 14 (5): 509–13CrossRefGoogle Scholar
  6. 6.
    Deierhoi MH, Hudson SL, Gaston RS. Clinical experience with a two dose regimen of daclizumab in cadaveric renal transplantation [abstract]. Transplantation 2000 Apr 27; 69 Suppl.: S260CrossRefGoogle Scholar
  7. 7.
    Nair MP, Nampoory MRN, Johny KV, et al. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients. Transplant Proc 2001 Aug; 33: 2767–9PubMedCrossRefGoogle Scholar
  8. 8.
    Chang GJ, Mahanty HD, Vincenti F, et al. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transpl 2000; 14 (6): 550–4CrossRefGoogle Scholar
  9. 9.
    Golconda MS, Rayhill SC, Hunsicker LG. Daclizumab permits delayed introduction of calcineurin inhibitors in renal transplant recipients at risk for delayed graft function [abstract]. Transplantation 2000 Apr 27; 69(8) Suppl.: S158CrossRefGoogle Scholar
  10. 10.
    Nevins T, Ettenger R, Potter D, et al. Daclizumab (Zenapax) in pediatric (PED) renal allografts: final data [abstract no.469]. Transplantation 1999; 67: S124CrossRefGoogle Scholar
  11. 11.
    Sarwal MM, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001 Jul 15; 72 (1): 13–21PubMedCrossRefGoogle Scholar
  12. 12.
    Kato T, Neff G, Montalbano M, et al. Steroid-free induction with tacrolimus and daclizumab in liver transplant recipients with hepatitis C — a preliminary report of a prospective randomized trial. Am J Transplant 2001; 1 Suppl. 1: 179Google Scholar
  13. 13.
    Pinna AD, Ricordi C, Weppler D, et al. Treatment of recurrent hepatitis C after liver transplantation with IL-2r antibody. Transplant Proc 2001 Feb-Mar; 33: 1087–9PubMedCrossRefGoogle Scholar
  14. 14.
    Heffron TG, Smallwood GA, de Vera M, et al. Hepatitis C recurrence following daclizumab induction in liver transplantation [abstract]. Hepatology 2000 Oct; 32 (Pt2): 346Google Scholar
  15. 15.
    Eckhoff DE, McGuire B, Sellers M, et al. The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation 2000; 69 (9): 1867–72PubMedCrossRefGoogle Scholar
  16. 16.
    Emre S, Gondolesi G, Polat K, et al. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2001 Mar; (7): 220–5PubMedCrossRefGoogle Scholar
  17. 17.
    Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000; 342 (9): 613–9PubMedCrossRefGoogle Scholar
  18. 18.
    Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized, anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95 (1): 83–9PubMedGoogle Scholar
  19. 19.
    Willenbacher W, Basara N, Kirsten D, et al. Treatment of severe steroid-resistant GVHD with a monoclonal interleukin-2 receptor agonist (daclizumab [DC]) [abstract]. Bone Marrow Transplant 2000 Mar; 25 Suppl. 1: S156Google Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations